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Abstract 
Background: Diabetic macular edema (DME) shows a gradual and sustained functional and morphologic response 
to anti-vascular endothelial growth factor (VEGF) drugs, but the optimal schedule for initiation of anti-VEGF therapy 
is not known. This study evaluates the treatment response behavior of DME in the Phase 3 trials of intravitreal afliber-
cept, with 5 initial intravitreal aflibercept injections (IAI), 2 mg every 4 weeks (2q4), in the upload phase.
Methods: This post hoc pooled analysis of the VISTA-DME (NCT01363440) and VIVID-DME (NCT01331681) trials 
evaluated the change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) during the upload 
phase, using pooled data from both IAI treatment groups [2q4 and 2 mg every 8 weeks (2q8)]. The mean visit-to-
visit change in BCVA and CRT, and the respective rate of gainers and losers was calculated for each successive visit. A 
secondary analysis compared the visit-to-visit change in BCVA between the 2q4 and 2q8 treatment arms during the 
upload period and the first year treatment period.
Results: The majority of eyes showed a continuing improvement of BCVA after the first IAI. The proportions of eyes 
gaining BCVA (≥5 letters) at each visit compared with the previous visit during the IAI 2q4 upload phase were 60 
(4-weeks), 19 (8-weeks), 16 (12-weeks), 15 (16-weeks), and 14 % (20-weeks). In contrast, the proportions of eyes los-
ing BCVA (≥5 letters) were 3 (4-weeks), 7 (8-weeks), 7 (12-weeks), 9 (16-weeks), and 8 % (20-weeks), respectively. The 
odds of BCVA (≥5 letters) gain/loss exceeded 1.7 at each visit (range 1.7–20). Overall, the proportion of patients with 
BCVA gain ≥5 letters at week 20 (compared with baseline) was 76 and 80 % in the 2q4 and 2q8 groups, respectively. 
The proportions of eyes showing a visit-to-visit decrease in CRT of ≥30 µm during the first 5 IAI were 77 (4-weeks), 
27 (8-weeks), 21 (12-weeks), 17 (16-weeks), and 12 % (20-weeks). In the secondary analysis, the BCVA outcomes were 
similar for the 2q8 and 2q4 treatment arms.
Conclusions: The data presented here are consistent with continual functional and anatomic improvement fol-
lowing the fourth and fifth initial 2q4 injections, suggesting that an intensive and sufficiently long upload may be 
beneficial.
Trial registration VIVID-DME: Clinicaltrials.gov: NCT01331681; VISTA-DME: Clinicaltrials.gov: NCT01363440
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Background
Intravitreal anti-vascular endothelial growth factor (VEGF) 
medications are recognized for improving visual outcomes 
and decreasing macular fluid in patients with diabetic 
macular edema (DME) [1–3]. In contrast to other retinal 
diseases, the response has been shown to be more “grad-
ual”—the curves of best-corrected visual acuity (BCVA) 
and central retinal thickness (CRT) more slowly approach 
their values of maximal improvement during the treatment 
every 4  weeks (Table  1; [4–12]), resulting in a long first 
phase of improvement [1]. Importantly, long-term studies 
have shown that the favorable outcome can be maintained 
for at least 3–5 years, with a significantly reduced number 
of treatments during the later follow-up [6].
What is less clear at this point, however, is the opti-
mal dosing schedule for initiation of anti-VEGF therapy 
in DME. Given that the disease is characterized by high 
levels of intravitreal VEGF [9], there is clearly a rationale 
for aggressive initial therapy; however, specific initiation 
algorithms have not been evaluated as the independ-
ent variable within Phase 3 clinical trials, and indirect 
comparisons-across study populations or drugs used-
are of limited value. The 36-month results from the 
DA VINCI study suggest that 5 initial 2  mg intravitreal 
aflibercept injections (IAI) may be beneficial, whereas 
the 2-year Protocol T results show that individualized 
initiation schemes that led to more than 5 doses for ini-
tiation resulted in a favorable outcome [13, 14]. There 
are currently no clearly defined predictors for identifying 
patients with DME who are in need of either an inten-
sified or less intensive initial treatment with anti-VEGF 
therapy.
A worldwide comparison showed a widespread diver-
sity of initiation recommendations for anti-VEGF treat-
ment in DME, ranging from series of 3, 4, or 5 to patterns 
of 4 + 2 injections [2, 15]. Some national guideline com-
mittees refrain from giving any specific guidance on the 
best initiation strategy [16]. Other recommendations 
define the dosing scheme in relation to the drug used 
(according to the study protocols) [16–19]. Still other 
societies suggest a minimum of 4 initial injections in 
accordance with the DRCR.net treatment protocol [20, 
21], which was also adopted in a slightly modified form in 
a recent head-to-head comparison of anti-VEGF drugs in 
the treatment of DME [9]. In the DRCR study, the major-
ity of patients received an intensive upload (6 monthly 
treatments initially) that was not mandated, suggesting 
the beneficial effects of a more intense initial schedule 
[2], with decreased dosing requirement seen in Year 2 
[15].
Aflibercept is a 115  kDa fusion protein composed of 
extracellular domains from human VEGF receptors 1 and 
2, and has been shown to inhibit both VEGF-A and pla-
cental growth factor (PGF) [22]. Preclinical studies have 
shown a long duration of action and high binding affinity 
to VEGF-A.
Given the variability in guidance and incomplete evi-
dence base, it may be valuable to examine more closely 
the efficacy data for a well-studied initiation protocol, IAI 
2 mg every 4 weeks (2q4) for 5 doses, and in particular to 
ascertain if there is evidence for continued improvement 
following the fourth and fifth injections in the series. This 
post hoc analysis evaluates the visit-to-visit visual acuity 
and CRT responses to the initial 5 IAI given in the Phase 
Table 1 Treatment initiation and continuation regimens of Phase 3 randomized controlled trial of anti-VEGF in DME
q4, every 4 weeks
* Within controlled/core study phase




Fixed q4 intervals ranibizumab









Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [7] Week 24
REVEAL
NCT00989989
Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [8] Week 32
DRCR protocol I
NCT00445003





Aggressive retreatment protocol for IAI, bevacizumab, and ranibizumab prior to 
24-week visit with q4 intervals [10]
Week 32, week 52
VIVID/VISTA
NCT01363440 NCT01331681
Initial 5 q4 intervals IAI followed by 2q8 or 2q4 intervals [11] Week 44
BOLT
EUDRACT2007-000847-89
Initial 3 q6 intervals bevacizumab (initially combined with laser) followed by PRN 
(protocol-driven) bevacizumab retreatment [12]
Week 100
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3 trials. This detailed look at the treatment response dur-
ing the upload phase provides greater clarity regarding 
the responsiveness of DME to this upload strategy.
Methods
VISTA and VIVID were 2 similarly designed, double-
masked, randomized, active-controlled, 148-week, Phase 
3 trials. VISTA was conducted across 54 sites in the 
United States, and VIVID took place in 73 sites across 
Europe, Japan, and Australia. Both VISTA and VIVID 
were conducted in compliance with the International 
Conference on Harmonisation guidelines and the Health 
Insurance Portability and Accountability Act of 1996. The 
study protocol has been described in detail [11]. Briefly, 
patients with central-involved DME (defined as retinal 
thickening involving the 1-mm central area as meas-
ured by optical coherence tomography) were eligible 
for enrollment if BCVA was between 73 and 24 letters 
(20/40–20/320 Snellen equivalent) in the study eye. After 
5 initial doses at 4-week intervals (IAI 2q4), IAI eyes 
received treatment in accordance with the protocol [2q4, 
2 mg every 8 weeks (2q8)].
This study was a post hoc analysis of the initial response 
to IAI treatment in the VISTA (NCT01363440) and 
VIVID (NCT01331681) trials, with BCVA performed per 
a defined protocol at every visit, OCT performed with a 
SD-OCT at every visit, and read by independent read-
ing centers. Pooled data included all patients in the full 
analysis set from both studies, defined as all randomized 
patients who received any investigational product and 
had a baseline and at least 1 post-baseline assessment of 
BCVA. We evaluated the change in the BCVA and the 
reduction in CRT from the immediately preceding visit 
to the immediately following visit for each of the first 5 
IAI 2q4 doses. This analysis was done for the pooled 
data from the 2q4 and 2q8 groups of VIVID and VISTA, 
as both groups received the same number of treatments 
during the upload phase. Therefore, the analysis reflects 
the approved dosing in both the European Medicines 
Agency and US Food and Drug Administration labels.
When assessing the visit-to-visit change, a threshold of 
5 Early Treatment Diabetic Retinopathy Study (ETDRS) 
letters and 30  µm was chosen as the cutoff for defining 
categorical change (for the responder analysis). These 
cutoff values were chosen, as lower thresholds would be 
more vulnerable to measurement variability. The change 
in retinal thickness of 30  µm corresponds to approxi-
mately one-tenth of the total thickness. The proportion 
of gainers and losers and the ratio of gainers/losers were 
calculated for each of the first 5 dosing intervals.
In addition, as a secondary analysis, the proportion of 
patients who gained ≥5 ETDRS letters from baseline was 
compared between the pooled 2q8 and the pooled 2q4 
treatment arms of VIVID and VISTA by for each follow-
up visit through week 72. Finally, we summarized the 
100-week safety data for these 2 pooled treatment groups 
in order to provide a more complete comparison.
Results
Upload analysis
There were 576 patients in the pooled full analysis set. 
The highest percentage of patients attaining visual gain 
of at least 5 letters was seen 4  weeks after the first IAI 
(59.8 %, Fig. 1). The lowest percentage of patients experi-
encing visual acuity loss of at least 5 letters was also seen 
4 weeks after the first IAI (2.6 %, Fig. 1). At 4 weeks fol-
lowing the fifth IAI, 14.4 % of patients (1 in 7) had BCVA 
gain ≥5 letters, while 8.0 % had BCVA loss of ≥5 letters 
(Fig.  1). The ratio of gainers to losers after the first IAI 
was 23.0; it decreased to 2.7 after the second IAI and 
remained around 2 subsequently (2.3, 1.7, and 1.8 after 
the third, fourth and fifth IAI, respectively). Thus there 
were more gainers than losers following all 5 treatments 
of initial 2q4 dosing (Figs. 1, 2). 
The anatomic response of these patients was supported 
by the CRT measurements showing similar proportions 
of reductions and increases (Fig. 3). The highest percent-
age of patients attaining reduction in CRT of ≥30 µm was 
seen 4 weeks after the first IAI (76.8 %, Fig. 3), as was the 
lowest percentage of patients with CRT increase (2.6 %). 
At 4  weeks following the fifth IAI, 12.0  % of patients 
(about 1 in 8) had CRT reduction of ≥30  µm whereas 
4.9  % had CRT increase of ≥30  µm. Thus, the ratio of 
gainers to losers after the first IAI was 29.5; it decreased 
after each subsequent IAI but was still 2.4 following the 
fifth IAI (Fig. 3).
Fig. 1 Percentage of patients who gained or lost 5 letters; change of 
BCVA is always compared with the previous visit (n = 576)
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Secondary analyses
The mean change in BCVA from baseline to each visit 
up to 72  weeks for the pooled 2q8 and the pooled 2q4 
arms of VIVID and VISTA is shown in Fig.  4. There is 
continuous improvement through week 20, represent-
ing the 4-week follow-up following the fifth IAI, with 
75.8 % of patients in the 2q4 and 79.8 % of patients in the 
2q8 groups gaining ≥5 letters at week 20. During fur-
ther treatment for 1  year, during which the 2q4 group 
received treatment every 4  weeks and the 2q8 group 
received treatment every 8 weeks, no large shifts of these 
proportions were observed for either dosage arm and the 
values were similar at each time point.
Safety
In both VISTA and VIVID, overall incidence of ocular 
and nonocular adverse events (AEs) was similar across 
treatment groups [11]. Over the course of the 100-week 
treatment period, there were no cases of endophthal-
mitis in any eyes treated with IAI in either study. The 
most common ocular AEs were conjunctival hemor-
rhage [99/291 (34.0  %) IAI 2q4, 81/287 (28.2  %) IAI 
2q8, and 180/578 (31.1 %) all IAI], cataract [36 (12.4 %), 
31 (10.8  %), 67 (11.6  %)], and eye pain [34 (11.7  %), 28 
(9.8 %), 62 (10.7 %)]. The most common non-ocular AEs, 
respectively, were hypertension [67 (23.0 %), 63 (22.0 %), 
130 (22.5 %)], nasopharyngitis [49 (16.8 %), 51 (17.8 %), 
100 (17.3 %)], and urinary tract infection [23 (7.9 %), 36 
(12.5 %), 59 (10.2 %)] [11]. Overall rates of Anti-Platelet 
Trialists’ Collaboration-defined arterial thromboembolic 
events, including vascular deaths, were low and compa-
rable across the treatment groups. The incidence of death 
in the IAI 2q4, IAI 2q8, and control groups was 5.2, 2.6, 
and 1.9 %, respectively, in VISTA, and 2.9, 4.4, and 0.8 % 
in VIVID [11]. Overall, the AE profile over the 100 weeks 
of the study was consistent with the known safety profile 
of IAI.
Discussion
This analysis illustrates the dynamic nature of the 
improvements in visual acuity during the upload phase, 
or first 20  weeks, of IAI 2q4 treatment. Specifically, in 
this analysis of pooled VIVID/VISTA data, we have 
shown that even though most shifts toward better visual 
acuity already occur after the very first injection, there 
Fig. 2 Waterfall plots of BCVA change at weeks 4, 8, and 12
Fig. 3 Visit-to-visit change in CRT: percentage of patients who had a 
reduction or increase in CRT of ≥30 µm (n = 576)
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are still considerably more BCVA gainers than losers fol-
lowing each of the subsequent 4 treatments during the 
IAI 2 q4 upload phase. This response in vision of patients 
with DME is paralleled by the CRT measurements show-
ing similar proportions of reductions and increases. 
Therefore, these data support the potential benefit of at 
least 5 initial IAI 2q4 as an upload treatment regimen.
We also showed that over the course of the subsequent 
52 weeks, during which one treatment arm received IAI 
2q8 and the other continued to receive IAI 2q4, the visual 
acuity efficacy results, as well as the safety results, were 
highly similar. These data indicate that the longer-term 
outcome appears to be similar with less frequent dosing 
after the upload phase.
The data presented here are consistent with what has 
been observed in other important studies of anti-VEGF 
treatment for DME (Table  1). As these studies have 
shown, the rise in visual acuity in DME is gradual and 
peak visual acuity is only established after 6–9 months or 
longer [23]. This suggests that the initial treatment phase 
is particularly critical for final treatment success [10, 24, 
25]. Although caution must be exercised when compar-
ing across studies, there seems to be a pattern demon-
strated in studies with a less intense/rigorous treatment 
initiation that outcomes may not be as good as outcomes 
in studies with a more rigorous and intense initiation 
scheme (e.g., RESTORE, Protocol I) [5, 6, 10].
With regard to IAI, the Phase 2 DA VINCI study 
showed for the first time that outcomes are similar with 
anIAI 2q8 dosing schedule compared with 2q4 or PRN 
dosing, and the requirement for monitoring can be 
reduced [13]. However, the study also suggests that visual 
acuity is less stable in the early treatment phase and that 
a more intensified treatment initiation could be benefi-
cial. Hence, in the Phase 3 studies for IAI, an additional 
dose was added at week 12, resulting in a sequence of 5 
initial IAI 2q4 before extending the treatment interval to 
2q8 in one of the treatment arms. In summary, the avail-
able data suggest that visual acuity in DME patients may 
be impacted by the number of initial treatments during 
the upload phase. Our analysis of the pooled data from 
the upload phase of VIVID and VISTA suggests that this 
vulnerable phase may best be managed with the inten-
sified dosing regimen of 5 initial consecutive doses at 
4-weeks intervals.
The implementation of an initial treatment series can 
minimize the risk of under-treatment. In particular for 
patient education, the concept of a consistent initiation 
series can enhance the attendance at follow-up visits and 
adherence to the therapy [26]. If patients understand 
the need for a strict retreatment, the chance of reach-
ing the maximum BCVA potential may be higher. A 
series of treatments can reduce organizational efforts 
and might minimize the impact of potential diagnostic 
Fig. 4 Percentage of patients who gained ≥5 letters from baseline, by visit
Page 6 of 7Ziemssen et al. Int J Retin Vitr  (2016) 2:16 
errors (optical coherence tomography criteria) at deci-
sion points. Moreover, the administration of 5 consecu-
tive IAIs does not preclude any additional interim fundus 
or safety examination, if considered necessary on a case-
by-case basis.
This analysis has important strengths. First, it is based 
on a large data set from 2 pivotal randomized con-
trolled trials of patients treated with the identical upload 
regimen. Second, it fills a gap in the field insofar as this 
particular regimen has not been well represented in pre-
vious analyses. Third, longer-term efficacy and safety 
strengthen the finding that following this particular 
upload regimen, outcomes remain similar despite less 
frequent IAI dosing (2q8 vs. 2q4).
This analysis also has several limitations. Only 1 load-
ing dose phase is analyzed; thus, no direct conclusions 
can be drawn about the comparative efficacy of this ini-
tial treatment schedule with any other treatment scheme. 
In addition, the duration of action of each injection is 
not necessarily limited to the first 4 weeks following the 
injection, as the long-term experience suggests a vascular 
remodeling in DME under anti-VEGF therapy [9]. Thus, 
the visit-to-visit change cannot be solely attributedto the 
most recent injection, but also to the previous treatment, 
as well asother confounding factors. Although the simple 
responder analysis of the visit-to-visit change, as carried 
out in this study and described in this article, does not 
allow for predicting or assessing the response of an indi-
vidual patient, it is supportive of an intensive treatment 
start, which is in line with observations that have been 
made in other studies.
Conclusions
This post hoc analysis has demonstrated continuous 
improvement during the treatment initiation schedule of 
5 IAI at 4-weeks intervals implemented in the VIVID and 
VISTA randomized clinical trials. These data support the 
potential benefit of this pragmatic treatment initiation 
strategy in the treatment of DME.
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